Show simple item record

dc.contributor.authorPerez-Lopez, R
dc.contributor.authorMateo, J
dc.contributor.authorMossop, H
dc.contributor.authorBlackledge, MD
dc.contributor.authorCollins, DJ
dc.contributor.authorRata, M
dc.contributor.authorMorgan, VA
dc.contributor.authorMacdonald, A
dc.contributor.authorSandhu, S
dc.contributor.authorLorente, D
dc.contributor.authorRescigno, P
dc.contributor.authorZafeiriou, Z
dc.contributor.authorBianchini, D
dc.contributor.authorPorta, N
dc.contributor.authorHall, E
dc.contributor.authorLeach, MO
dc.contributor.authorde Bono, JS
dc.contributor.authorKoh, D-M
dc.contributor.authorTunariu, N
dc.date.accessioned2016-08-23T10:37:36Z
dc.date.issued2017-04
dc.identifier.citationRadiology, 2017, 283 (1), pp. 168 - 177
dc.identifier.issn0033-8419
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/71
dc.identifier.eissn1527-1315
dc.identifier.doi10.1148/radiol.2016160646
dc.description.abstractPurpose To determine the usefulness of whole-body diffusion-weighted imaging (DWI) to assess the response of bone metastases to treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). Materials and Methods A phase II prospective clinical trial of the poly-(adenosine diphosphate-ribose) polymerase inhibitor olaparib in mCRPC included a prospective magnetic resonance (MR) imaging substudy; the study was approved by the institutional research board, and written informed consent was obtained. Whole-body DWI was performed at baseline and after 12 weeks of olaparib administration by using 1.5-T MR imaging. Areas of abnormal signal intensity on DWI images in keeping with bone metastases were delineated to derive total diffusion volume (tDV); five target lesions were also evaluated. Associations of changes in volume of bone metastases and median apparent diffusion coefficient (ADC) with response to treatment were assessed by using the Mann-Whitney test and logistic regression; correlation with prostate-specific antigen level and circulating tumor cell count were assessed by using Spearman correlation (r). Results Twenty-one patients were included. All six responders to olaparib showed a decrease in tDV, while no decrease was observed in all nonresponders; this difference between responders and nonresponders was significant (P = .001). Increases in median ADC were associated with increased odds of response (odds ratio, 1.08; 95% confidence interval [CI]: 1.00, 1.15; P = .04). A positive association was detected between changes in tDV and best percentage change in prostate-specific antigen level and circulating tumor cell count (r = 0.63 [95% CI: 0.27, 0.83] and r = 0.77 [95% CI: 0.51, 0.90], respectively). When assessing five target lesions, decreases in volume were associated with response (odds ratio for volume increase, 0.89; 95% CI: 0.80, 0.99; P = .037). Conclusion This pilot study showed that decreases in volume and increases in median ADC of bone metastases assessed with whole-body DWI can potentially be used as indicators of response to olaparib in mCRPC. Online supplemental material is available for this article.
dc.formatPrint-Electronic
dc.format.extent168 - 177
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectBone Neoplasms
dc.subjectProstatic Neoplasms
dc.subjectPiperazines
dc.subjectPhthalazines
dc.subjectAntineoplastic Agents
dc.subjectDiffusion Magnetic Resonance Imaging
dc.subjectTreatment Outcome
dc.subjectProspective Studies
dc.subjectPilot Projects
dc.subjectImage Processing, Computer-Assisted
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectWhole Body Imaging
dc.subjectBiomarkers, Tumor
dc.titleDiffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
dc.typeJournal Article
dcterms.dateAccepted2016-08-01
rioxxterms.versionofrecord10.1148/radiol.2016160646
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfRadiology
pubs.issue1
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume283
pubs.embargo.termsNo embargo
icr.researchteamClinical Trials & Statistics Uniten_US
icr.researchteamICR-CTSU Urology and Head and Neck Trials Teamen_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamComputational Imagingen_US
icr.researchteamMagnetic Resonanceen_US
dc.contributor.icrauthorMossop, Helenen
dc.contributor.icrauthorRata, Mihaelaen
dc.contributor.icrauthorRescigno, Pasqualeen
dc.contributor.icrauthorLeach, Martinen
dc.contributor.icrauthorBlackledge, Matthewen
dc.contributor.icrauthorPorta, Nuriaen
dc.contributor.icrauthorHall, Emmaen
dc.contributor.icrauthorDe Bono, Johannen
dc.contributor.icrauthorKoh, Dow-Muen
dc.contributor.icrauthorTunariu, Ninaen
dc.contributor.icrauthorMarsden,en
dc.contributor.icrauthorMateo Valderrama, Joaquinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0